|
|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
News and Press Releases |
 |
TransCure bioServices delivers CDX mouse models to advance AML preclinical studies
Archamps, 6 March 2023 – TransCure bioServices has developed cell
line-derived xenograft (CDX) mouse models that will change how
researchers tackle the preclinical studies of cancer therapies to treat
acute myeloid leukemia (AML). These models enable deeper insights into
the efficacy and toxicity of AML therapies, leading to the development
of better treatments and bringing hope to the thousands of patients that
receive an AML diagnosis each year.
More info >> |
|
|
